2-[4-(piperidin-1-yl)piperidin-1-yl]-5-bromopyrimidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[4-(piperidin-1-yl)piperidin-1-yl]-5-bromopyrimidine
• 英文别名: 5-bromo-2-(4-piperidin-1-ylpiperidin-1-yl)pyrimidine
• 化学式: C₁₄H₂₁BrN₄
• mdl: MFCD19019833
• 分子量: 325.252
• InChiKey: NSCLGEYEMWTTLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.714
• 拓扑面积：
  32.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-[4-(piperidin-1-yl)piperidin-1-yl]-5-bromopyrimidine 、 对氨基苯腈 在 tris-(dibenzylideneacetone)dipalladium(0) 、 sodium t-butanolate 、 2-二环己基磷-2,4,6-三异丙基联苯 作用下， 以 1,4-二氧六环 为溶剂， 反应 1.0h， 以89%的产率得到4-((2-([1,4'-bipiperidin]-1'-yl)pyrimidin-5-yl)amino)benzonitrile
  参考文献：
  名称：

  微波辅助2,5-二取代的嘧啶衍生物的合成通过Buchwald-Hartwig偶联反应

  摘要：

  在Buchwald-Hartwig胺化的微波辐射下，合成了各种2，5-二取代的嘧啶衍生物。这种简洁的方法以高到高的产量提供了有趣的支架，并且具有大的官能团相容性。这些新颖的化学实体可以用作药物设计的基础。

  DOI：

  10.1016/j.tetlet.2019.151406
• 作为产物：
  描述：

  4-哌啶基哌啶 、 5-溴-2-氯嘧啶 在 caesium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 16.0h， 以69%的产率得到2-[4-(piperidin-1-yl)piperidin-1-yl]-5-bromopyrimidine
  参考文献：
  名称：

  PIPERIDINE DERIVATIVES

  摘要：

  公开号：

  EP1669350B1

文献信息

• Novel piperidine derivative
  申请人：Ohtake Norikazu

  公开号：US20070105901A1

  公开（公告）日：2007-05-10

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder, and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X 1 and X 2 independently represent a nitrogen atom or CH; Y represents a specific group; X 3 represents O s —(CH 2 ) m ; R 1 and R 2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  本发明提供了一种组胺H3受体拮抗剂；以及预防和/或治疗代谢系统疾病，例如肥胖症、糖尿病、激素分泌障碍、高脂血症、痛风、脂肪肝、循环系统疾病，例如心绞痛、急性/充血性心力衰竭、心肌梗塞、冠状动脉硬化、高血压、肾病、睡眠障碍以及伴随着睡眠障碍的各种疾病，例如特发性嗜睡症、反复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律障碍、慢性疲劳综合征、REM睡眠障碍、老年失眠、夜班工人睡眠不卫生、特发性失眠、反复性失眠、真性失眠、电解质代谢障碍，以及中枢和外周神经系统疾病，例如贪食症、情绪障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、认知障碍、运动障碍、感觉异常、嗅觉障碍、癫痫、吗啡耐受、麻醉剂依赖、酒精依赖等的预防和/或治疗剂。该组胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH；Y表示特定基团；X3表示Os—（CH2）m；R1和R2独立地表示氢原子、卤素原子、线性或支链低碳基、低碳氧基或2或3个氟原子取代的乙酰基；s为0或1；m是一个使（m+s）为0或1至4的整数]或其药学上可接受的盐。
• Piperidine derivative
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07834182B2

  公开（公告）日：2010-11-16

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver, circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnia, repetitive hypersomnia, true hypersomnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic insomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific group; X3 represents Os—(CH2)m; R1 and R2 independently resent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substituted with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  提供了一种组织胺H3受体拮抗剂；以及一种预防和/或治疗代谢系统疾病的药物，例如肥胖症、糖尿病、激素分泌障碍、高脂血症、痛风、脂肪肝、循环系统疾病，例如心绞痛、急性/充血性心力衰竭、心肌梗死、冠状动脉硬化、高血压、肾病、睡眠障碍以及伴随睡眠障碍的各种疾病，例如特发性嗜睡症、反复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律紊乱、慢性疲劳综合征、REM睡眠障碍、老年失眠症、夜班工人睡眠不良、特发性失眠症、反复性失眠症、真性失眠症、电解质代谢障碍；以及中枢和外周神经系统疾病，例如暴食症、情绪障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、认知障碍、运动障碍、感觉异常、嗅觉障碍、癫痫、吗啡耐受性、麻醉药依赖性、酒精依赖性。 组织胺H3受体拮抗剂包括式（I）的哌啶衍生物化合物[其中X1和X2独立地表示氮原子或CH；Y表示特定基团；X3表示Os-（CH2）m；R1和R2独立地表示氢原子、卤素原子、线性或支链低级烷基、低级烷氧基或2或3个氟原子取代的乙酰基；s为0或1；m是一个整数，使（m+s）为0或从1到4]，或其药学上可接受的盐。
• NOVEL PIPERIDINE DERIVATIVE
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1669350A1

  公开（公告）日：2006-06-14

  Provided are a histamine-H3 receptor antagonist; and a preventive and/or a remedy for metabolic system diseases such as obesity, diabetes, hormone secretion disorder, hyperlipemia, gout, fatty liver; circulatory system diseases, for example, stenocardia, acute/congestive cardiac insufficiency, cardiac infarction, coronary arteriosclerosis, hypertension, nephropathy, sleep disorder and various diseases accompanied by sleep disorder such as idiopathic hypersomnnia, repetitive hypetsomnnia, true hypersomnnia, narcolepsy, sleep periodic acromotion disorder, sleep apnea syndrome, circadian rhythm disorder, chronic fatigue syndrome, REM sleep disorder, senile insomnia, night worker sleep insanitation, idiopathic imsomnia, repetitive insomnia, true insomnia, electrolyte metabolism disorder; and central and peripheral nervous system diseases such as bulimia, emotional disorder, melancholia, anxiety, epilepsy, delirium, dementia, shinzophrenia, attention deficit/hyperactivity disorder, memory disorder, Alzheimer's disease, Parkinson's disease, sleep disorder, recognition disorder, motion disorder, paresthesia, dysosmia, epilepsy, morphine resistance, narcotic dependency, alcoholic dependency. The histamine-H3 receptor antagonist comprises a piperidine derivative compound of formula (I) [wherein X1 and X2 independently represent a nitrogen atom or CH; Y represents a specific goup; X3 represents Os-(CH2)m; R1 and R2 independently represent a hydrogen atom, a halogen atom, a linear or branched lower alkyl group, a lower alkoxy group, or an acetyl group substitued with 2 or 3 fluorine atoms; s is 0 or 1; and m is an integer to make (m+s) 0 or from 1 to 4], or its pharmaceutically-acceptable salt.

  本发明提供了一种组胺-H3 受体拮抗剂；以及一种预防和/或治疗代谢系统疾病的药物，例如肥胖症、糖尿病、激素分泌紊乱、高脂血症、痛风、脂肪肝；循环系统疾病，如心血管狭窄、急性/充血性心功能不全、心肌梗塞、冠状动脉硬化、高血压、肾病、睡眠障碍和伴有睡眠障碍的各种疾病，如特发性嗜睡症、重复性嗜睡症、真性嗜睡症、嗜睡症、睡眠周期性运动障碍、睡眠呼吸暂停综合征、昼夜节律紊乱、慢性疲劳综合征、快速眼动睡眠障碍、老年性失眠症、夜班工人睡眠失调症、特发性失眠症、重复性失眠症、真性失眠症、电解质代谢紊乱；以及中枢和周围神经系统疾病，如贪食症、情感障碍、忧郁症、焦虑症、癫痫、谵妄、痴呆、新精神分裂症、注意力缺陷/多动障碍、记忆障碍、阿尔茨海默病、帕金森病、睡眠障碍、识别障碍、运动障碍、麻痹、嗅觉障碍、癫痫、吗啡抵抗、麻醉品依赖、酒精依赖。组胺-H3 受体拮抗剂包括式（I）的哌啶衍生物化合物[其中 X1 和 X2 独立地代表氮原子或 CH；Y 代表特定基团；X3 代表 Os-(CH2)m；R1和R2独立地代表氢原子、卤素原子、直链或支链低级烷基、低级烷氧基或被2或3个氟原子取代的乙酰基；s为0或1；m为整数，使(m+s)为0或1至4]，或其药学上可接受的盐。
• US7547693B2
  申请人：——

  公开号：US7547693B2

  公开（公告）日：2009-06-16
• US7834182B2
  申请人：——

  公开号：US7834182B2

  公开（公告）日：2010-11-16